It’s that time of year again where we zoom in on the top pharma and biopharma companies based on revenues. In 2017 combined sales of the Top 25 Pharma & Biopharma Companies profiled in our report totaled $599 billion, nearly on par with last year’s $602 billion mark. Nineteen of the top 25 companies reported positive growth. With 33%, 16% and 14% revenue hikes, Shire, Celgene and Boehringer-Ingelheim saw the most growth. At the same time, Gilead’s 13% sales decrease represented the biggest loss from the previous year.

Pfizer continues to hold its post at the top of the heap and by a wide margin. More than $10 billion in sales separates itself from Roche. Novartis’ slide out of the top 5 was the most dramatic drop in this year’s report with its four spot fall from 2 to 6. No other company fell back more than three positions.

With Merck and GSK also falling back a couple spots, the way was paved for Roche’s climb to number 2 and Sanofi and J&J’s entry into the top 5 at positions 3 and 4 respectively.

Movement in the middle of the pack was pretty minor. Lilly made the furtherest leap ahead in the ranks from 13 last year up three spots to round out the top 10. At the bottom of the list, Boehringer-Ingelheim fell furthest from 16 to 19, and with Merck KGaA falling out of the report entirely, it made way for Astellas’ reemergence.

01. Pfizer $52,546
02. Roche $42,219
03. Sanofi $41,991
04. Johnson & Johnson $36,256
05. Merck & Co. $35,390
06. Novartis $33,025
07. GlaxoSmithKline $30,270
08. AbbVie $28,216
09. Gilead $26,107
10. Eli Lilly & Co. $22,871
11. Amgen $22,849
12. AstraZeneca $22,465
13. Teva $22,385
14. Bristol-Myers Squibb $20,776
15. Bayer $20,180
16. Novo Nordisk $17,966
17. Takeda $16,663
18. Allergan $15,941
19. Boehringer Ingelheim $15,930
20. Shire $14,449
21. Celgene $13,003
22. Biogen $12,274
23. Astellas $12,238
24. Mylan $11,908
25. Otsuka $11,006

Contributors

Editor: Tim Wright
Managing Editor: Kristin Brooks
Associate Editor: Betsy Louda


*Profile information is sourced from each company’s annual report along with press releases distributed throughout the year. Pharma/biopharmaceutical sales are the primary factor in the rankings, however results may include animal heath sales where applicable and other smaller division sales. Large medical device, diagnostics, and consumer care division revenues have been excluded from the rankings. Thank you for your time!